Stephanie Léouzon

Stephanie Léouzon

Partner and Head of Torreya Partners Europe

London Office

+44 20 7451 4551

in

Stephanie Léouzon joined Torreya Partners in 2011 and has previously worked on over 100 strategic and financing transactions in the biopharmaceutical industry valued in excess of $75 billion.

Her experience includes a number of strategic advisory and financing assignments, including the $34.6 billion Astra and Zeneca merger, the $6.8 billion Pharmacia & Upjohn merger, Hoechst’s $7 billion acquisition of Marion Merrell Dow, the creation of Syngenta through the merger of the agricultural businesses of AstraZeneca and Novartis and the $3.1 billion Warner Chilcott LBO.

She has also led teams for several financings across a number of health care sectors, with a special focus on the biotechnology and specialty pharma sectors. She has worked on over 15 Initial Public Offerings (IPOs) including Movetis, Warner Chilcott, Syngenta, GPC Biotech, Ark Therapeutics, Actelion, Prostrakan, Jerini, BioXell, Walsh International, IDEXX Labs, Viropharma, Pharmaceutical Marketing Services Inc., Neurex Corp and Geron Corp.  Past other financings (Secondaries, Convertibles, Private Placements) have included National Health Laboratories, Marion Merrell Dow, Galen, Basilea, Oxford Glycosciences, BTG Therapeutics, Gilead Sciences, Advanced Medicine (Theravance), Skye Pharma, Centocor, Ark Therapeutics, American Medical Response, Pharmaceutical Marketing Services, PowderJect, Oxagen, Inpharmatica, Cetus Corporation, Virco Holdings, Cytogen Corporation and NaPro Biotherapeutics. A notable debt financing was the $2.4 billion bank and high yield financings for the LBO of Warner Chilcott.

Other M&A transactions where she has acted as advisor include the sale of PowderJect to Chiron Corporation; the acquisition of LEK by Novartis; the sale of Warner Chilcott Inc. to Galen Holdings PLC; the sale of Jerini AG to Shire PLC; the sale of Preglem SA to Gedeon Richter; the acquisition by Novartis of Mead Johnson Adult Medical Nutrition Business; the sale of Cantab PLC to Xenova PLC; the acquisition of Arakis by Sosei; the sale of AstraZeneca’s Dental Local Anesthetics Business to Dentsply; the acquisition by PowderJect of Medeva Vaccines; the divestiture of RPR’s Diététique et Santé to Sandoz; the divestiture of two RPR business units to Johnson & Johnson; the divestiture of Marion Merrell Dow’s Colla-Tec to Integra Life Sciences; a strategic Alliance for Draxis’s Anipryl with Pfizer Animal Health; the divestiture of Novartis’s Nutrition et Santé to ABN Amro Capital; the acquisition of a minority stake in Nordic Laboratories for Marion Merrell Dow; the sale of Helsinn’s Portugese business to Gruppo Angelini and the acquisition of Trinity Pharmaceuticals by Chiesi.

Stephanie earned a B.A. from Mount Holyoke College, cum laude in 1985 and then earned an MBA from the Darden School at the University of Virginia in 1989. She was an Associate and then Vice President at Lehman Brothers and then moved to JP Morgan as a Vice President (1993-1996). After joining Salomon Brothers as a Director in Healthcare Investment Banking in 1996, she joined Credit Suisse in London where she worked from 1997-2010 as a Director, then Managing Director and Senior Advisor. She currently serves on the Executive Committee of Women Innovating Together in Healthcare (W.I.T.H.), as a Non-Executive Director of Immunovaccine Inc and chairs the committee for the Great Ormond Street Hospital Christmas Carol Concert.